Oslo, Norway, 18 August 2004
PhotoCure ASA, Galderma S.A, DUSA Pharmaceuticals Inc. and Queens University at Kingston, announced today that they have entered into a mediation agreement designed to facilitate resolution of the parties' potential patent disputes concerning PhotoCure and Galdermas Metvix® (methyl aminolevulinate) product.
PhotoCure received 27 July 2004 approval from the U.S. Food and Drug Administration (FDA) for its novel product methyl aminolevulinate for photodynamic treatment of actinic keratosis (sun-induced, pre-cancerous skin condition). DUSA's product, the Levulan® Kerastick® has been approved for treatment of actinic keratoses using photodynamic therapy since September, 2000.